The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples